Carboplatin

• CAT Number: A001041
• CAS Number: 41575-94-4
• Molecular Formula: C6H12N2O4Pt
• Molecular Weight: 371.30
• Purity: ≥95%
• Synonyms: JM-8, CBDCA, NSC 241240; Carboplatinum; 41575-94-4; Cbdca; Paraplatin; Carbopaltin
• Target: DNA Synthesis
• Solubility: Limited solubility
• Storage: -20°C
• IUPAC Name: azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
• InChI: InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
• InChIKey: VSRXQHXAPYXROS-UHFFFAOYSA-N
• SMILES: C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

Carboplatin（Cat No.:A001041）is a platinum-based chemotherapy drug used to treat various cancers, including ovarian, lung, bladder, and testicular cancers. It works by forming DNA cross-links, disrupting the DNA structure and preventing cancer cells from dividing and replicating. Carboplatin is often preferred over cisplatin due to its reduced toxicity profile, particularly concerning nephrotoxicity and nausea. However, it can still cause side effects such as myelosuppression, peripheral neuropathy, and hypersensitivity reactions. Carboplatin is frequently used in combination with other chemotherapy agents to enhance its effectiveness and improve treatment outcomes for patients.

Reference

1: Ito M, Horita N, Nagashima A, Kaneko T. Carboplatin plus pemetrexed for the
elderly incurable chemo-naive nonsquamous non-small cell lung cancer:
Meta-analysis. Asia Pac J Clin Oncol. 2018 Jan 8. doi: 10.1111/ajco.12837. [Epub
ahead of print] PubMed PMID: 29316288.

2: Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow E, Kong L, Yu F, Peethala
PC, Wong AL, Laljibhai HJ, Chinnathambi A, Ong PS, Ho PC, Sethi G, Yong WP, Goh
BC. Pan-HDAC inhibition by panobinostat mediates chemosensitization to
carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
Cancer Lett. 2018 Jan 3. pii: S0304-3835(18)30003-X. doi:
10.1016/j.canlet.2017.12.030. [Epub ahead of print] PubMed PMID: 29306016.

3: Snee M. Quality of life comparing carboplatin with cisplatin in the treatment
of non-small cell lung cancer. Eur J Cancer. 2018 Jan 2. pii:
S0959-8049(17)31427-2. doi: 10.1016/j.ejca.2017.11.019. [Epub ahead of print]
PubMed PMID: 29301719.

4: Dunn LA, Fury MG, Xiao H, Baxi SS, Sherman EJ, Korte S, Pfister C, Haque S,
Katabi N, Ho AL, Pfister DG. A phase II study of temsirolimus added to low-dose
weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic
(R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2018 Jan 2. doi:
10.1093/annonc/mdx801. [Epub ahead of print] PubMed PMID: 29300804.

5: Furubayashi N, Negishi T, Yamashita T, Kusano S, Taguchi K, Shimokawa M,
Nakamura M. The combination of paclitaxel and carboplatin as second-line
chemotherapy can be a preferred regimen for patients with urothelial carcinoma
after the failure of gemcitabine and cisplatin chemotherapy. Mol Clin Oncol. 2017
Dec;7(6):1112-1118. doi: 10.3892/mco.2017.1452. Epub 2017 Oct 13. PubMed PMID:
29285384; PubMed Central PMCID: PMC5740837.

6: Bouman-Wammes EW, van den Berg HP, de Munck L, Beeker A, Smorenburg CH,
Vervenne WL, Coenen JLLM, Verheul HMW, Gerritsen WR, Van den Eertwegh AJM. A
randomised phase II trial of docetaxel versus docetaxel plus carboplatin in
patients with castration-resistant prostate cancer who have progressed after
response to prior docetaxel chemotherapy: The RECARDO trial. Eur J Cancer. 2017
Dec 18;90:1-9. doi: 10.1016/j.ejca.2017.11.021. [Epub ahead of print] PubMed
PMID: 29268139.

7: Chen X, Wang J, Fu Z, Zhu B, Wang J, Guan S, Hua Z. Curcumin activates DNA
repair pathway in bone marrow to improve carboplatin-induced myelosuppression.
Sci Rep. 2017 Dec 18;7(1):17724. doi: 10.1038/s41598-017-16436-9. PubMed PMID:
29255221; PubMed Central PMCID: PMC5735145.

8: Zhu T, Xu F, Zhang L, Zhang Y, Yang C, Cheng M, Chen F, Wang K. Measurement of
molecular biomarkers that predict the tumor response in estrogen
receptor-positive breast cancers after dose-dense (biweekly)
paclitaxel/carboplatin neoadjuvant chemotherapy. Oncotarget. 2017 Jul
28;8(60):101087-101094. doi: 10.18632/oncotarget.19686. eCollection 2017 Nov 24.
PubMed PMID: 29254147; PubMed Central PMCID: PMC5731857.

9: Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio Perilongo, Grill J,
Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R,
Faldum A, Kilmartin D, De Paoli A, De Salvo GL; Low Grade Glioma Consortium and
the participating centers. Corrigendum to /A European randomised controlled trial
of the addition of etoposide to standard vincristine and carboplatin induction as
part of an 18-month treatment programme for childhood (≤16 years) low grade
glioma – A final report/ [Eur J of Canc (2017) 206-225]. Eur J Cancer. 2017 Dec
13. pii: S0959-8049(17)31415-6. doi: 10.1016/j.ejca.2017.11.017. [Epub ahead of
print] PubMed PMID: 29248309.

10: Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination
with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco
Targets Ther. 2017 Dec 1;10:5739-5744. doi: 10.2147/OTT.S145934. eCollection
2017. PubMed PMID: 29238206; PubMed Central PMCID: PMC5716301.